Jacob Asset Management of New York’s Beam Therapeutics BEAM Stock Holding History

Jacob Asset Management of New York’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$116K	Buy	4,829 +435	+10%	+$11.7K	0.16%	61
2023 Q2	$140K	Sell	4,394 -72	-2%	-$2.34K	0.16%	61
2023 Q1	$137K	Hold	4,466	–	–	0.16%	60
2022 Q4	$175K	Buy	4,466 +329	+8%	+$14.7K	0.21%	58
2022 Q3	$197K	Buy	4,137 +333	+9%	+$19K	0.21%	58
2022 Q2	$147K	Buy	3,804 +810	+27%	+$32.2K	0.15%	66
2022 Q1	$172K	Buy	+2,994	New	+$196K	0.1%	69

Other funds holding BEAM

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Jacob Asset Management of New York's BEAM Position: Q3 2023 in Review

Jacob Asset Management of New York increased its Beam Therapeutics (BEAM) stake by 9.9% in Q3 2023, buying an estimated $11.7K and bringing the position to 4,829 shares worth $116K. The position accounts for 0.16% of the portfolio, ranked #61.

Jacob Asset Management of New York first reported a position in BEAM in Q1 2022 and has held it in 7 quarters since. The position peaked at $197K in Q3 2022. 194 funds tracked by Wall St. Rank hold BEAM as of Q3 2023.

Jacob Asset Management of New York held 4,829 shares of Beam Therapeutics worth $116K as of Q3 2023.
Jacob Asset Management of New York bought 435 Beam Therapeutics shares in Q3 2023, an estimated $11.7K.
Beam Therapeutics made up 0.16% of Jacob Asset Management of New York's portfolio in Q3 2023, its #61 holding.
Jacob Asset Management of New York first reported a position in Beam Therapeutics in Q1 2022 and has held it in 7 quarters since.
Jacob Asset Management of New York's Beam Therapeutics position peaked at $197K in Q3 2022.
194 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2023.

Based on Jacob Asset Management of New York's 13F filing for Q3 2023, filed 1 Nov 2023.